{"contentid": 488748, "importid": NaN, "name": "Ysios Capital closes its third fund at $260 million", "introduction": "Ysios Capital, Spain\u00e2\u0080\u0099s largest and leading European venture capital firm specialized in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million euros ($260 million).", "content": "<p>Ysios Capital, Spain&rsquo;s largest and leading European venture capital firm specialized in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million euros ($260 million).</p>\n<p>YBF 3 &ndash; Ysios&rsquo; largest fund to date &ndash; provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need, supporting pioneering businesses striving to make a difference in patients' lives.</p>\n<p>YBF 3 will invest broadly across multiple therapeutic areas and modalities, targeting seed/early stage and development-stage companies at the forefront of the future of medicine. The total investment size per company will typically be up to 20 million euros.</p>\n<p>Ysios takes lead positions and works closely with entrepreneurial management teams. Emphasis will be placed on building sustainable companies with business models offering dual paths to liquidity. As with previous funds, about 80% of the YBF 3 investments will target Europe, with a special focus on Spain, while the remainder of the fund will target opportunities in North America.</p>\n<h2><strong>Investments </strong></h2>\n<p>More than 60% of the portfolio has already been constructed, with eight investments made in the last 12 months by blue-chip European and US investors. YBF 3 has participated in the following fund raisings, mostly taking a lead or co-lead role:</p>\n<ul>\n<li>Ona Therapeutics (Oncology, Spain) &ndash; 30 million euros Series A</li>\n<li>SpliceBio (Gene therapy, Spain) &ndash; Seed/company build-up</li>\n<li>VarmX (Blood clotting, The Netherlands) &ndash; 32 million euros Series B</li>\n<li>Lava Therapeutics (Oncology, Netherlands) &ndash; 70 million euros Series C/IPO (Nasdaq: LVTX $103 million)</li>\n<li>SparingVision (Gene therapy, France) &ndash; 44.5 million euros Series A2 round</li>\n<li>Synendos (Neuropsychiatry, Switzerland) &ndash; 24 million Swiss francs Series A</li>\n<li>Adcendo (Oncology, Denmark) &ndash; 51 million euros Series A</li>\n<li>Cytoki (Inflammation, Denmark) &ndash; 38 million euros Series A</li>\n</ul>\n<p>Commenting on the close, Ysios Capital managing partner Jo&euml;l-Mairet, said: &ldquo;Our latest close is testament to the stellar track record we have built up at Ysios over the last ten years, securing investment beyond our initial target size. The quality of this company portfolio, exemplified by the recent IPO on NASDAQ of Lava Therapeutics shortly after our initial investment demonstrates the role we play in driving forward the future of medicine.&rdquo;</p>\n<p>&nbsp;</p>", "date": "2021-05-26 14:50:00", "meta_title": "Ysios Capital closes its third fund at $260 million", "meta_keywords": "Ysios Capital, Venture, Funding, Investments", "meta_description": "Ysios Capital closes its third fund at $260 million", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-26 14:49:28", "updated": "2021-05-26 14:55:25", "access": NaN, "url": "https://www.thepharmaletter.com/article/ysios-capital-closes-its-third-fund-at-260-million", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "money_drugs_scales_large-1-.jpg", "image2id": "money_drugs_scales_small-1-.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": NaN, "topic_tag": "Business Financing", "geography_tag": "Spain", "company_tag": "Ysios Capital", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-26 14:50:00"}